Navigation Links
Depression not discussed during rheumatoid arthritis doctor visits
Date:2/1/2008

Patients with rheumatoid arthritis (RA), the most common chronic inflammatory arthritis, are twice as likely as other individuals to experience depression. Although depression in primary care has been well studied, no studies have examined whether rheumatologists and RA patients discuss depression during medical visits. A new study published in the February issue of Arthritis Care & Research (http://www.interscience.wiley.com/journal/arthritiscare) found that patients whose activities were more restricted due to their arthritis were more than twice as likely to have moderately severe to severe symptoms of depression. It also found that few depressed patients discussed their condition with their rheumatologists and the subject was always brought up by the patients as opposed to the physicians.

Led by Betsy Sleath, of the University of North Carolina at Chapel Hill, NC, the study included 200 RA patients from four rheumatology clinics with eight participating doctors. Patient visits were audiotaped and patients were interviewed after their medical visits using a questionnaire to measure their mental status.

The results showed that almost 11% of the patients in the study had moderately severe to severe symptoms of depression and that those who were rated as being more restricted in their normal activities were significantly more likely to have these symptoms. Furthermore, only 1 in 5 of the patients who showed symptoms discussed depression with their rheumatologists and they were always the ones to bring up the topic. Even when depression was brought up, it was often not discussed at any length.

When patients visit their rheumatologists, their main focus is their RA, yet such chronic diseases can greatly impact a patients psychosocial well-being. In addition, many RA patients see their rheumatologists more often then their primary care physician and depression can also affect a patients adherence to treatment regimens. For these reasons the authors suggest that it is important for rheumatologists to consider addressing both the RA and the depression when they see their patients. The authors note that some physicians may not feel comfortable discussing depression with their patients, but they should consider having their office staff administer a brief depression screening before the patients visits in order to identify problems early on.

In addition to screening for depression, the authors suggest it is important for patients to have access to appropriate treatment. Rheumatologists can treat the depression themselves, refer patients to a mental health professional, or communicate with the patients primary care physician to coordinate a treatment plan. Also, given how common depression is in these patients, rheumatology training programs should educate physicians about the importance of screening for and treating depression.

Failure to detect and treat depression may compromise patients adherence to regimens and, ultimately, their health outcomes, the authors conclude. Future research should examine patient- and physician-reported barriers to communicating about depression in rheumatology practices and use these findings to design innovative interventions that can be delivered effectively in busy rheumatologist practices.


'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Blue Cross of California Launches Maternity Depression Program
2. Depression and anxiety can double chances of heart ailments
3. Depression, Obesity Coexist in Many Middle-Aged Women
4. Walk away menopausal anxiety, stress and depression
5. Realistic Expectations Help Ward Off Holiday Depression
6. Kaiser Permanente -- Group Health study shows depression worsens HIV treatment
7. Treating Depression Cuts Diabetes Death Risk
8. Blue Cross Blue Shield of Michigan Foundation Funds Study Exploring Link between Heart Disease and Depression
9. Lack of Light and Seasonal Depression - Whats the Link? From the Harvard Health Letter
10. Venlafaxine extended-release effective for patients with major depression
11. New studies on cancer and schizophrenia, depression and heart disease, trauma and autism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... San Francisco, CA (PRWEB) , ... May 26, 2016 , ... ... 1st, 2016, from 6pm to 7.30pm PST at HP in Palo Alto, CA. This ... panel discussion will be led by clinical trial experts from the pharmaceutical company Hallux, ...
(Date:5/25/2016)... ... May 25, 2016 , ... “We are ... Partner at HealthScape Advisors. “Brad brings significant experience advising healthcare provider clients throughout ... accelerates with the implementation of MACRA, we believe that continuing to add professionals ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... The Georgia ... Award of Excellence from the Atlanta Urban Design Commission. , The annual award recognizes ... city of Atlanta’s built environment, the preservation of its physical heritage and the balance ...
(Date:5/25/2016)... ... 2016 , ... Serenity Recovery, a holistic treatment center for ... the many supplemental program options offered at their rehabilitation facility, this time focusing ... Belt in the Shorin-ryu style of Karate that originated in Okinawa, Japan, and ...
(Date:5/25/2016)... ... ... to an article published May 5th on The Daily Mail, a survey pointed ... it found that more than a third cited unappealing breath a one of their top ... a failure to brush after meals, can typically be attributed to gum disease. Moreover, the ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25,2016 ... the near-infrared Cellvizio platform for urological and surgical ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal ... regulatory milestone in the US with the 12 ... and Drug Administration (FDA). This new FDA clearance ...
(Date:5/25/2016)... India , May 25, 2016 ... Animation Market by Type (3D, 2D, 4D), by Therapeutic ... Education), by End User (Medical Device Manufacturers, Hospitals/ Clinics) ... studies the global Medical Animation Market for the forecast ... to reach USD 301.3 Million by 2021 from USD ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 /PRNewswire/ ... dringenden Bedarf zur Steuerung ... N.V. (NASDAQ: QGEN ; Frankfurt Prime ... Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur Entwicklung und ... sein. Ein erstes Projekt wird die Entwicklung und ...
Breaking Medicine Technology: